Cover Image

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review

Abstract The prevalence of cutaneous adverse events attributable to newly approved anti-cancer drugs has been well reviewed in the dermatologic literature. In contrast, over 75% of US Food and Drug Administration approvals in the past 5 years have been for non-cancer drugs and indications. This repr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paul C. Macklis (Author), Brittany Dulmage (Author), Brady Evans (Author), Misha Rosenbach (Author), Johann E. Gudjonsson (Author), Benjamin H. Kaffenberger (Author)
Format:	Book
Published:	Adis, Springer Healthcare, 2020-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System
by: Giuseppe Cicala, et al.
Published: (2024)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024)

Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023)

FDA approved ready to use phenylephrine
by: Pradeep Kumar Bhatia, et al.
Published: (2021)

An overview of FDA-approved vaccines & their innovators
by: Rebekah H. Griesenauer, et al.
Published: (2017)

Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib
by: Paul Macklis, MS, et al.
Published: (2021)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

Adverse events of targeted therapies approved for women's cancers
by: Mathilde Saint-Ghislain, MD, et al.
Published: (2021)

FDA approved injection drug against schizophrenia
by: article Editorial
Published: (2023)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
by: Jyothi Dhuguru, et al.
Published: (2022)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System
by: Mengling Ouyang, et al.
Published: (2024)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
by: Xianglin Pan, et al.
Published: (2024)

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System
by: Huqun Li, et al.
Published: (2024)

Causes of Drug-Induced Severe Cutaneous Adverse Reaction Epidermal Necrolysis (EN): An Analysis Using FDA Adverse Event Reporting System (FAERS) Database
by: Fei W, et al.
Published: (2023)

FDA approval of Pfizer-BioNTech: Evaluating the significance of mRNA vaccine approval
by: Syed Abdullah Monawwer, et al.
Published: (2021)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024)

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Kaibin Niu, et al.
Published: (2024)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
by: Si Su, et al.
Published: (2023)

FDA-approved drugs in 2022: A brief outline
by: Haitham Ahmed Al-Madhagi
Published: (2023)

The FDA has approved the first treatment for Friedreich's ataxia
by: article Editorial
Published: (2023)

FDA approves belimumab for treatment of children with lupus nephritis
by: article Editorial
Published: (2022)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
by: Hao Zhong, et al.
Published: (2018)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024)

Adverse drug reactions in neonates: a brief analysis of the FDA adverse event reporting system
by: Pernille Kähler Byskov, et al.
Published: (2024)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
by: Pan Ma, et al.
Published: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
by: Qiang Guo, et al.
Published: (2022)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022)

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Jiahong Zhong, et al.
Published: (2024)

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Zhengkang Su, et al.
Published: (2024)

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
by: Yue He, et al.
Published: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
by: Xusheng Zhang, et al.
Published: (2024)

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer
by: Anna Jo Bodurtha Smith, et al.
Published: (2024)

Ebanga™: The most recent FDA-approved drug for treating Ebola
by: Elahe Taki, et al.
Published: (2023)